ATE550074T1 - Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril - Google Patents
Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitrilInfo
- Publication number
- ATE550074T1 ATE550074T1 AT05779369T AT05779369T ATE550074T1 AT E550074 T1 ATE550074 T1 AT E550074T1 AT 05779369 T AT05779369 T AT 05779369T AT 05779369 T AT05779369 T AT 05779369T AT E550074 T1 ATE550074 T1 AT E550074T1
- Authority
- AT
- Austria
- Prior art keywords
- amino
- cyanoethenyl
- fumarate
- pyrimidinyl
- dimethylphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| EP05101447 | 2005-02-25 | ||
| PCT/EP2005/054341 WO2006024667A1 (en) | 2004-09-02 | 2005-09-02 | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE550074T1 true ATE550074T1 (de) | 2012-04-15 |
Family
ID=38091631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05779369T ATE550074T1 (de) | 2004-09-02 | 2005-09-02 | Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090215804A1 (de) |
| EP (1) | EP1789139B1 (de) |
| JP (1) | JP4922937B2 (de) |
| KR (1) | KR101276571B1 (de) |
| AP (1) | AP2487A (de) |
| AT (1) | ATE550074T1 (de) |
| AU (1) | AU2005279157B2 (de) |
| BR (1) | BRPI0514861A (de) |
| CA (1) | CA2577273C (de) |
| CR (1) | CR9032A (de) |
| DK (1) | DK1789139T3 (de) |
| EA (1) | EA011036B1 (de) |
| ES (1) | ES2384715T3 (de) |
| HR (1) | HRP20120499T1 (de) |
| IL (1) | IL181649A0 (de) |
| MX (1) | MX2007002594A (de) |
| NI (1) | NI200700069A (de) |
| NO (1) | NO339788B1 (de) |
| SI (1) | SI1789139T1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2702044B1 (de) | 2011-04-25 | 2017-03-22 | Hetero Research Foundation | Verfahren für rilpivirin |
| KR20220077143A (ko) * | 2019-10-10 | 2022-06-08 | 악셀라 헬스 인크. | 아미노산 엔티티를 포함하는 부피가 감소된 제형물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498419A (en) * | 1994-06-03 | 1996-03-12 | Pars; Harry G. | Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric |
| EP0951278A2 (de) * | 1997-01-03 | 1999-10-27 | ELAN CORPORATION, Plc | Minitablette formulierung zur verzögerte freigabe von cisapride |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| DK1529032T3 (da) * | 2002-08-09 | 2013-07-08 | Janssen Pharmaceutica Nv | Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| BRPI0407329A (pt) * | 2003-02-07 | 2006-01-10 | Janssen Pharmaceutica Nv | Derivados de pirimidina para a prevenção de infecção de hiv |
| EP1596838A2 (de) * | 2003-02-11 | 2005-11-23 | Torrent Pharmaceuticals Ltd | Orale zubereitungen zur anwendung einmal am tag mit einem protonenpumpenhemmer und einem prokinetischen wirkstoff |
-
2005
- 2005-09-02 HR HRP20120499TT patent/HRP20120499T1/hr unknown
- 2005-09-02 EP EP05779369A patent/EP1789139B1/de not_active Expired - Lifetime
- 2005-09-02 JP JP2007528885A patent/JP4922937B2/ja not_active Expired - Lifetime
- 2005-09-02 ES ES05779369T patent/ES2384715T3/es not_active Expired - Lifetime
- 2005-09-02 AU AU2005279157A patent/AU2005279157B2/en not_active Expired
- 2005-09-02 SI SI200531539T patent/SI1789139T1/sl unknown
- 2005-09-02 BR BRPI0514861-8A patent/BRPI0514861A/pt not_active Application Discontinuation
- 2005-09-02 KR KR1020077006376A patent/KR101276571B1/ko not_active Expired - Lifetime
- 2005-09-02 US US11/574,452 patent/US20090215804A1/en not_active Abandoned
- 2005-09-02 AT AT05779369T patent/ATE550074T1/de active
- 2005-09-02 AP AP2007003933A patent/AP2487A/xx active
- 2005-09-02 DK DK05779369.7T patent/DK1789139T3/da active
- 2005-09-02 MX MX2007002594A patent/MX2007002594A/es active IP Right Grant
- 2005-09-02 CA CA2577273A patent/CA2577273C/en not_active Expired - Lifetime
- 2005-09-02 EA EA200700534A patent/EA011036B1/ru unknown
-
2007
- 2007-03-01 IL IL181649A patent/IL181649A0/en active IP Right Grant
- 2007-03-01 NI NI200700069A patent/NI200700069A/es unknown
- 2007-03-30 CR CR9032A patent/CR9032A/es not_active Application Discontinuation
- 2007-04-02 NO NO20071720A patent/NO339788B1/no unknown
-
2011
- 2011-03-04 US US13/040,465 patent/US20110150996A1/en not_active Abandoned
-
2017
- 2017-12-22 US US15/852,181 patent/US20180116964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA200700534A1 (ru) | 2007-08-31 |
| EP1789139B1 (de) | 2012-03-21 |
| HK1112862A1 (en) | 2008-09-19 |
| IL181649A0 (en) | 2007-07-04 |
| HRP20120499T1 (hr) | 2012-07-31 |
| AU2005279157B2 (en) | 2011-07-14 |
| AP2487A (en) | 2012-10-03 |
| KR20070053284A (ko) | 2007-05-23 |
| NO20071720L (no) | 2007-04-02 |
| NO339788B1 (no) | 2017-01-30 |
| ES2384715T3 (es) | 2012-07-11 |
| CR9032A (es) | 2009-07-30 |
| SI1789139T1 (sl) | 2012-08-31 |
| AU2005279157A1 (en) | 2006-03-09 |
| EA011036B1 (ru) | 2008-12-30 |
| JP2008511591A (ja) | 2008-04-17 |
| NI200700069A (es) | 2015-12-10 |
| JP4922937B2 (ja) | 2012-04-25 |
| US20180116964A1 (en) | 2018-05-03 |
| AP2007003933A0 (en) | 2007-04-30 |
| KR101276571B1 (ko) | 2013-06-18 |
| DK1789139T3 (da) | 2012-07-09 |
| US20090215804A1 (en) | 2009-08-27 |
| BRPI0514861A (pt) | 2008-06-24 |
| EP1789139A1 (de) | 2007-05-30 |
| MX2007002594A (es) | 2007-04-25 |
| CA2577273C (en) | 2013-11-19 |
| CA2577273A1 (en) | 2006-03-09 |
| US20110150996A1 (en) | 2011-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1600060I1 (hu) | 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| MEP33808A (hr) | Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze | |
| TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
| MX338920B (es) | Proceso para la preparacion de compuestos de aminocrotonilo. | |
| JO2515B1 (en) | Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it | |
| WO2009007441A3 (en) | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile | |
| NO20050524L (no) | Fremgangsmater for fremstillingen av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril | |
| NO20042844L (no) | 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister | |
| TW200609001A (en) | Particulate-stabilized injectable pharmaceutical compositions of posaconasole | |
| ATE541573T1 (de) | Pharmazeutische zusammensetzung enthaltend lapatinib | |
| IL181649A0 (en) | Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino) benzonitrile | |
| UA92469C2 (en) | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile | |
| EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
| HRP20110563T1 (en) | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| SE0103476D0 (sv) | New use | |
| ITMI20020639A1 (it) | Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea | |
| UY27049A1 (es) | Composiciones farmacéuticas |